An Expanded Access Program to Axitinib is Available for Patients With Advanced Forms of Kidney Ca… (NCT05941637) | Clinical Trial Compass
NO_LONGER_AVAILABLENot Applicable
An Expanded Access Program to Axitinib is Available for Patients With Advanced Forms of Kidney Cancer (Ductal; Papillary; Chromophobic; Oncocytic) With Mutations in VHL, PBRM1 / BAP1, SETD2, VEGF)
Plain-language summary
Kidney cancer belongs to a heterogeneous group of tumors and is the most common oncourological disease; up to 80% of cases are clear cell carcinoma.
Who can participate
Age range18 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Histologically documented metastatic renal cell cancer or cell kidney cancer
* Evidence of measurable disease.
* Adequate renal function (serum creatinine level)
* ECOG Status 0-1
* Patient must provide signed informed consent
* Male or female, age \>/= 18 years
Exclusion Criteria:
* Current use or anticipated need for treatment with drugs that are known potent CYP3A4 inhibitors
* Current use or anticipated need for treatment with drugs that are known as potent CYP3A4 or CYP1A2.
* Active gastrointestinal bleeding.
* Severe allergic reactions
* Unwillingness or inability to comply with mandated pretreatment biopsy or therapeutic regimen